Medicine and Dentistry
Vitamin D
60%
Supplementation
60%
Patient
55%
Early Psychosis
38%
Psychosis
30%
Randomized Clinical Trial
30%
Neuroprotection
30%
Antidepressant Medication
30%
Premature Mortality
30%
Cohort Analysis
30%
Group Trial
30%
Positive and Negative Syndrome Scale
25%
Mortality
21%
Hazard Ratio
17%
Male
13%
Follow up
13%
Global Assessment of Functioning
12%
Mental Health
12%
Diagnosis
11%
Health Outcomes
11%
Therapeutic Procedure
10%
Association
10%
Calgary Depression Scale
9%
Hospital
9%
Socioeconomic Status
7%
Gender
7%
Age
6%
Ethnic Groups
6%
Disability
6%
Racial Group
6%
Symptom
6%
Vitamin D Deficiency
6%
C Reactive Protein
6%
Colecalciferol
6%
Body Mass Index
6%
Pharmacology, Toxicology and Pharmaceutical Science
Schizophrenia
100%
Cohort Study
60%
Case Report
39%
Antipsychotic
38%
Tolerability
34%
Sodium Valproate
30%
Neuroprotection
30%
Case-Control Study
30%
Controlled Clinical Trial
30%
Randomized Controlled Trial
12%
Pharmacotherapy
7%
Route of Administration
7%
Penfluridol
7%
Asenapine
7%
Mood Stabilizer
6%
Nursing and Health Professions
Patient
42%
Control
34%
Systematic Review
30%
Hospital
6%
Data Base
6%
Female
6%
Male
6%
Clinical Practice
6%
Gender
5%
